Document is current
Any future updates will be listed below
-
Authors
Seidel, Maximilian
Seibert, Felix S.
Anft, Moritz
Stervbo, Ulrik
Babel, Nina
Westhoff, Timm H.
Bertram, Sebastian
-
Funding
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
- License Information
-
More Information
Article History
Received: 13 April 2026
Accepted: 5 August 2026
First Online: 15 August 2026
Declarations
Ethics approval and consent to participate: The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee/institutional review board of the Ruhr-University Bochum (approval number: 15-5279). Written informed consent was obtained from all participants prior to inclusion in the study.
Consent for publication: All participants provided informed consent to the pseudonymized processing of their data and to the publication of the resulting data in anonymized form.
Competing interests: MS, FSS, and THW have received honoraria from Novartis for lectures. In addition, Novartis provided institutional research funding for a previous study conducted by their research group (“Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”). The present study received no funding from Novartis. All other authors declare that they have no competing interests.
